Report overview
Recombinant vaccines are produced using recombinant DNA technology, with the help of a vector. These vaccines stimulate the immune system of an individual and provide immunity against various lethal disease.
These vaccines are safe and have less or no side-effects as compared to conventional vaccines, in the prevention of various diseases such as influenza, cholera, typhoid, and dengue.
Recombinant vaccines are also used in animals for prevention of diseases such as foot and mouth disease, pneumonia and septicemia, and pox disease. Vaccination results in the prevention of disease, by producing antibodies against the protein antigen of pathogenic microorganisms.
This report aims to provide a comprehensive presentation of the global market for Recombinant Vaccines, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Recombinant Vaccines. This report contains market size and forecasts of Recombinant Vaccines in global, including the following market information:
Global Recombinant Vaccines Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global Recombinant Vaccines Market Sales, 2018-2023, 2024-2029, (K Units)
Global top five Recombinant Vaccines companies in 2022 (%)
The global Recombinant Vaccines market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
There is increase in the demand for livestock products, which in turn has increased growth of the animal recombinant vaccine segment and Europe dominates the animal recombinant vaccines market as compared to other regions due to highly organized livestock and huge demand of livestock product for the European population.
We surveyed the Recombinant Vaccines manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Recombinant Vaccines Market, by Type, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Recombinant Vaccines Market Segment Percentages, by Type, 2022 (%)
Subunit Recombinant Vaccines
Attenuated Recombinant Vaccines
Vector Recombinant Vaccines
Global Recombinant Vaccines Market, by Application, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Recombinant Vaccines Market Segment Percentages, by Application, 2022 (%)
Recombinant Human Vaccines
Animal Recombinant Vaccines
Global Recombinant Vaccines Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Recombinant Vaccines Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Recombinant Vaccines revenues in global market, 2018-2023 (Estimated), ($ millions)
Key companies Recombinant Vaccines revenues share in global market, 2022 (%)
Key companies Recombinant Vaccines sales in global market, 2018-2023 (Estimated), (K Units)
Key companies Recombinant Vaccines sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Merck & Co., Inc
Green Cross Corporation
Pfizer Inc.
Bayer AG
Sanofi S A.
Protein Science Corporation
GlaxoSmithKline Plc.
Novartis AG
Bharat Biotech
Outline of Major Chapters:
Chapter 1: Introduces the definition of Recombinant Vaccines, market overview.
Chapter 2: Global Recombinant Vaccines market size in revenue and volume.
Chapter 3: Detailed analysis of Recombinant Vaccines manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Recombinant Vaccines in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Recombinant Vaccines capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.
